Patients, Pricing, and Prescription Drugs
Skip to content
The Insightful Leader Live: What to Know about Today’s AI—and Tomorrow’s | Register Now
Healthcare Social Impact Economics Policy Mar 5, 2012

Patients, Pricing, and Prescription Drugs

Maximizing social benefit from the Medicaid drug program

Based on the research of

Peter Klibanoff

Tapas Kundu

As sponsors of the Medicaid program, the federal and state governments bear most of the cost of prescription drugs for Medicaid patients.

These drug sales are high volume, accounting for approximately 18.5 percent of the U.S. prescription drug market in 2002. Before 1990, Medicaid received no special rebates, but thanks to federal legislation passed that year, it is entitled to discounted prices in the form of rebates on each item.

These rebates are tied to the prices pharmaceutical companies charge non-Medicaid buyers of the same drug, a link that gives firms a profit incentive to adjust their prices compared to what they would choose without the legislation. Those adjustments not only affect company revenue but also impact the overall cost and quantity of Medicaid drugs for the government. They also affect drug costs and quantities for non-Medicaid buyers.

Calculating how companies should respond to the rebates and determining the impact of their responses on drug costs and demand have proved to be difficult problems. Now, however, Peter Klibanoff, an associate professor of managerial economics and decision sciences at the Kellogg School of Management, and Tapas Kundu, a research associate at the University of Oslo, have developed a model that analyzes the pricing strategies and allows policymakers to calculate the overall social costs of the two different approaches that the legislation mandated be used to calculate the rebates. “We are the first to fully work out what a pharma’s optimal response to these rebate policies would be,” Klibanoff says. “And to my knowledge we’re the first to ask if this would be good or bad for social welfare.”

The legislation requires two calculations of the rebate amount for each transaction: a minimum price rule and an average price rule. Whichever amount is higher, the government receives as its discount. Under the minimum price rule, the rebate is calculated as the difference between the minimum price for which a manufacturer sells a drug and the drug’s average price. Under the average price rule, the rebate is simply a fraction of the average price of any particular drug. Klibanoff and Kundu set out to determine how pharmaceutical manufacturers would guarantee their own best interests in dealing with each of these rebate rules and see what could be said about the social benefits of the policy.

Modeling the Problem
The pair used standard economic theory to build the model of manufacturers’ likely responses to the pricing process, and took a strictly analytical approach to the issue. “We have looked at previous researchers’ analyses, but we didn’t go back to the data,” Klibanoff says. “Our main contribution was modeling the problem in the way we did and fully solving it out.”

There is often a range of prices charged for a single drug, varying according to the organizations—such as HMOs, hospitals, or retail pharmacies—that buy the medications. Klibanoff and Kundu’s model shows how—in order to maximize their profits—drug makers would adjust their prices in response to the two ways of calculating rebates.

Under the minimum price rule, Klibanoff says, manufacturers would definitely want to increase the lowest prices they charged for a given drug before the government imposed the rule for its Medicaid patients. But for channels where that drug already commanded higher prices, pharmas would react to the minimum price rule by leveling off those prices or even decreasing them.

 “If the demand from consumers covered by Medicaid is sufficiently insensitive to price, all prices would decrease,” Klibanoff explains.

By contrast, the model shows that pharmas’ optimal response in the case of the average price rule would be to shift all the prices in the same direction—up or down. “If the demand from consumers covered by Medicaid is sufficiently insensitive to price, all prices would decrease,” Klibanoff explains. “But if Medicaid consumers are just as price-sensitive as consumers not covered by Medicaid, all prices would increase.”

By incorporating how drug makers and purchasers optimally respond to pricing regulations, the model provides guidance to government regulators on how their pricing policies will affect social welfare by taking into account both the well-being of consumers and the profits of the drug manufacturers.

“We’re saying: ‘Here are conditions under which society as a whole would benefit from these rebate rules and here are circumstances under which it would not’,” Klibanoff explains.

“The analysis of these policies is surprisingly intricate, even in a relatively simple setting such as ours,” Klibanoff and Kundu point out in their paper. “This suggests that great care is needed when implementing [most-favored-customer] rules and that making provisions for data collection to support follow-up empirical work measuring the pricing and demand response has high potential value in avoiding mistakes or helping fine-tune the policy.”

Beyond Medicaid
The paper also emphasizes the model’s value beyond the specific case of Medicaid. “Understanding the effects of these regulations is not simply of interest for evaluation of Medicaid policy, but is also important as a guide to future regulation,” the pair writes. “For example, recently there has been debate about the appropriate regulatory regime to govern drug purchases and reimbursement under Medicare.”

Klibanoff adds a specific recommendation. “Hopefully, for future policies of this kind and future decisions related to reimbursement, the model points out the need to build a monitoring system to see if the policy is creating good or harm,” he says. “The model can help focus those efforts.”

“It should encourage policymakers to think of strategic effects rather than just the direct effects that will arise from policies,” Klibanoff says. “Our paper shows that there may be a very sophisticated response to pricing policy on the part of the manufacturers and that, as a result, such a policy might be a good or bad idea. The devil’s in the details, and we provide some of the details you want to look at.”

Related reading on Kellogg Insight

Games Hospitals Play: How hospitals cope with competition

The Devil Is in the Detailing: Modeling physician choice of prescription drugs

Talk to Your Doctor About… How consumer drug ads affect prescribing practices

Featured Faculty

John L. and Helen Kellogg Professor of Managerial Economics & Decision Sciences

About the Writer
Peter Gwynne is a freelance writer based in Sandwich, Mass.
About the Research

Klibanoff, Peter and Tapas Kundu. 2010. “Monopoly Pricing under a Medicaid-Style Most-Favored-Customer Clause and Its Welfare Implication.” The B.E. Journal of Economic Analysis & Policy. 10(1): Article 77.

Most Popular This Week
  1. What Went Wrong at Silicon Valley Bank?
    And how can it be avoided next time? A new analysis sheds light on vulnerabilities within the U.S. banking industry.
    People visit a bank
  2. How Are Black–White Biracial People Perceived in Terms of Race?
    Understanding the answer—and why black and white Americans may percieve biracial people differently—is increasingly important in a multiracial society.
    How are biracial people perceived in terms of race
  3. What Went Wrong at AIG?
    Unpacking the insurance giant's collapse during the 2008 financial crisis.
    What went wrong during the AIG financial crisis?
  4. Will AI Eventually Replace Doctors?
    Maybe not entirely. But the doctor–patient relationship is likely to change dramatically.
    doctors offices in small nodules
  5. Which Form of Government Is Best?
    Democracies may not outlast dictatorships, but they adapt better.
    Is democracy the best form of government?
  6. Podcast: "It's Hard to Regulate U.S. Banks!"
    Silicon Valley Bank spectacularly collapsed—and a new analysis suggests that its precarious situation is not as much of an outlier as we’d hope. On this episode of The Insightful Leader, we learn what went wrong and what should happen next.
  7. What Happens to Worker Productivity after a Minimum Wage Increase?
    A pay raise boosts productivity for some—but the impact on the bottom line is more complicated.
    employees unload pallets from a truck using hand carts
  8. Why Do Some People Succeed after Failing, While Others Continue to Flounder?
    A new study dispels some of the mystery behind success after failure.
    Scientists build a staircase from paper
  9. Marketers, Don’t Be Too Hasty to Act on Data
    Don’t like the trends you’re seeing? It’s tempting to take immediate action. Instead, consider a hypothesis-driven approach to solving your problems.
    CEO stands before large data wall
  10. Why Well-Meaning NGOs Sometimes Do More Harm than Good
    Studies of aid groups in Ghana and Uganda show why it’s so important to coordinate with local governments and institutions.
    To succeed, foreign aid and health programs need buy-in and coordination with local partners.
  11. Understanding the Pandemic’s Lasting Impact on Real Estate
    Work-from-home has stuck around. What does this mean for residential and commercial real-estate markets?
    realtor showing converted office building to family
  12. How Has Marketing Changed over the Past Half-Century?
    Phil Kotler’s groundbreaking textbook came out 55 years ago. Sixteen editions later, he and coauthor Alexander Chernev discuss how big data, social media, and purpose-driven branding are moving the field forward.
    people in 1967 and 2022 react to advertising
  13. How Much Do Campaign Ads Matter?
    Tone is key, according to new research, which found that a change in TV ad strategy could have altered the results of the 2000 presidential election.
    Political advertisements on television next to polling place
  14. How Peer Pressure Can Lead Teens to Underachieve—Even in Schools Where It’s “Cool to Be Smart”
    New research offers lessons for administrators hoping to improve student performance.
    Eager student raises hand while other student hesitates.
  15. Immigrants to the U.S. Create More Jobs than They Take
    A new study finds that immigrants are far more likely to found companies—both large and small—than native-born Americans.
    Immigrant CEO welcomes new hires
  16. Leaders, Don’t Be Afraid to Admit Your Flaws
    We prefer to work for people who can make themselves vulnerable, a new study finds. But there are limits.
    person removes mask to show less happy face
  17. For Students with Disabilities, Discrimination Starts Before They Even Enter School
    Public-school principals are less welcoming to prospective families with disabled children—particularly when they’re Black.
    child in wheelchair facing padlocked school doors
  18. Executive Presence Isn’t One-Size-Fits-All. Here’s How to Develop Yours.
    A professor and executive coach unpacks this seemingly elusive trait.
    woman standing confidently
  19. How Self-Reflection Can Make You a Better Leader
    Setting aside 15 minutes a day can help you prioritize, prepare, and build a stronger team
    Self-reflection improves leadership over time
Add Insight to your inbox.
More in Healthcare